Royalty Pharma (RPRX) Stock Insights
RPRX$65.93+1.11 +1.71%
$29.36B
Market Cap
26.89
P/E
12.39
Forward P/E
51
Score
Royalty Pharma (RPRX) Stock Insights
RPRX price $65.93 +1.11 +1.71%
- Ticker
- RPRX
- Price
- $65.93
- Change
- +1.11 +1.71%
- Market cap ?
- $29.36B
- P/E ?
- 26.89
- Forward P/E ?
- 12.39
- Dividend yield ?
- 1.43%
- Beta ?
- 0.41
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Stocklytics score
- 51
- Value
- 47
- Quality
- 68
- Growth
- 39
Stocklytics score rationale: value 47, quality 68, growth 39.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1877410000 | 1597930000 | 1794894000 | 1814254000 | 2122353000 | 2289463000 | 2237215000 | 2354554000 | 2263576000 | 2378193000 |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was…
Insights
- Revenue by product
| Period | Value |
|---|---|
| FY2020 | Financial Royalty Assets: 1959975000.0, Intangible Royalty Assets: 143382000.0, Royalty Income, Other: 18996000.0 |
| FY2021 | Financial Royalty Assets: 2065083000.0, Intangible Royalty Assets: 171248000.0, Royalty Income, Other: 53132000.0 |
| FY2022 | Financial Royalty Assets: 2125096000.0, Intangible Royalty Assets: 37484000.0, Royalty Income, Other: 74635000.0 |
| FY2023 | Financial Royalty Assets: 2197754000.0, Intangible Royalty Assets: 835000.0, Royalty Income, Other: 155965000.0 |
| FY2024 | Financial Royalty Assets: 2149422000.0, Royalty Income, Other: 114154000.0 |
| FY2025 | Financial Royalty Assets: 2261152000.0, Royalty Income, Other: 117041000.0 |
Insights · Dividends · Forecast · Financials · Learn